Credit Suisse Downgrades Sarepta Therapeutics to Hold

By Ryan Adsit

Sarepta Therapeutics (NASDAQ: SRPT) received a Hold rating and an $81 price target from Credit Suisse analyst Alethia Young yesterday. The company’s shares closed yesterday at $79.10, close to its 52-week high of $80.23.

According to, Young is a 4-star analyst with an average return of 5.8% and a 50.4% success rate. Young covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Ionis Pharmaceuticals Inc, and Alexion Pharmaceuticals.

Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $75.77.

The company has a one-year high of $80.23 and a one-year low of $28.14. Currently, Sarepta Therapeutics has an average volume of 1.62M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sarepta Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. It focuses on the development of its potentially disease-modifying DMD drug candidates.